Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07566338 · ClinicalTrials.gov registry record · Phase 1

A Study of LY4302814 in Healthy Participants

A Phase 1 study, sponsored by Eli Lilly and Company.

Recruiting
Registry status
Phase 1
Development phase
150
Enrollment target

NCT07566338 is a Phase 1 study that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 150 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07566338, a Phase 1 study, is actively recruiting participants, sponsored by Eli Lilly and Company.

RECRUITING
Registry status
Phase 1
Development phase
150 participants
Enrollment target

Study Summary

The main purpose of this study is to assess how well LY4302814 is tolerated and what side effects may occur in healthy participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant, the study will last about 6 months and will include at least one overnight stay in the clinical research unit (CRU) lasting up to approximately 9 days.

Interventions

  • DRUG Placebo
  • DRUG LY4302814

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2026-05-06
Est. Completion 2027-08
Phase Phase 1

Sponsor

Eli Lilly and Company

1,341 total trials

What the Registry Record Tells You About NCT07566338

The ClinicalTrials.gov registry entry for NCT07566338 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT07566338 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT07566338 about?

NCT07566338 is a clinical study titled "A Study of LY4302814 in Healthy Participants". The main purpose of this study is to assess how well LY4302814 is tolerated and what side effects may occur in healthy participants. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. For each participant, the study will last a...

What is the current status of trial NCT07566338?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2026-05-06. Estimated completion is 2027-08.

What interventions are being tested in trial NCT07566338?

The interventions under investigation include: Placebo (DRUG), LY4302814 (DRUG).

Who is sponsoring clinical trial NCT07566338?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.